Sorafenib for advanced hepatocellular carcinoma
| Status: |
History |
| Expected date of issue: |
January 2010 |
| Referral date: |
June 2008 |
| Wave: |
17 |
| Process: |
STA |
| Topic area:
|
NICE project team
| Executive Lead: |
Gillian Leng
|
| Technical Lead: |
Faye McCracken
|
| Communications manager: |
Sarita Tamber
|
| Project manager: |
Laura Malone
|
Provisional schedule
| Closing date for invited submissions / evidence submission: |
14 January 2009 |
| 1st appraisal committee meeting: |
08 April 2009 |
| 2nd appraisal committee meeting |
11 June 2009 |
| 3rd appraisal committee meeting: |
12 August 2009 |
Consultees and commentators
|
| Consultees |
Commentators (no right of appeal) |
|
Manufacturers/sponsors
Patient/carer groups
- British Liver Trust
- Hepatitis B Foundation UK
- Hepatitis C Trust
- Rarer Cancers Forum
Professional groups
- British Association of the Study of the Liver
- Cancer Networks Pharmacists Forum
- Cancer Research UK
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians, Medical Oncology Joint Special Committee
- Royal College of Radiologists
Others
- Department of Health
- Oxfordshire PCT
- Welsh Assembly Government
|
General
- Department of Health, Social Services and Public Safety for Northern Ireland
- NHS Quality Improvement Scotland
Comparator manufacturer(s)
- Bayer (doxorubicin)
- Eli Lilly & Co. (gemcitabine)
- Pfizer (doxorubicin, cisplatin)
Relevant research groups
- Foundation for Liver Research
- MRC Clinical Trials Unit
Evidence Review Group
- West Midlands Health Technology Assessment Collaboration
- National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme)
Associated Guideline Groups
- National Collaborating Centre for Cancer
Associated Public Health Groups
|
|
Project history
| Date |
Update |
| 21 July 2009 |
The Appraisal Committee discussed sorafenib for the treatment of advanced hepatocellular carcinoma on 11 June 2009.
NICE has now been informed that the marketing authorisation holder for sorafenib (Bayer Healthcare) has agreed a patient access scheme with the Department of Health. In order to allow for consideration of the impact of the patient access scheme on clinical and cost effectiveness, the Appraisal Committee will discuss this topic again at its meeting on 12 August 2009.
|
|
Key documents
This page was last updated: 27 May 2010
